Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2025 Earnings Call Transcript August 5, 2025
Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.02, expectations were $-0.17.
Operator: Hello, ladies and gentlemen, and thank you for standing by, and welcome to Esperion’s Second Quarter 2025 financial results. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the conference over to Alina Venezia, Head of Investor...
